#ASCO21: Allogene sets out to prove that their off-the-shelf approach to CAR-T can beat the personalized approach

John Carroll

Editor & Founder

Allogene, the next-gen CAR-T company out to prove that their off-the-shelf approach to treating blood cancers is just as good as the autologous pioneers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO21: Allogene sets out to prove that their off-the-shelf approach to CAR-T can beat the personalized approach

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

#AS­CO21: Al­lo­gene sets out to prove that their off-the-shelf ap­proach to CAR-T can beat the per­son­al­ized ap­proach

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#ASCO21: Allogene sets out to prove that their off-the-shelf approach to CAR-T can beat the personalized approach